Rising Medical Solutions Publishes 12th Annual Workers' Compensation Benchmarking Study
CHICAGO, Aug. 6, 2025 /PRNewswire/ -- Rising Medical Solutions today announced the release of its 12th annual Workers' Compensation Benchmarking Study Report. The newly published study examines how claims organizations are successfully navigating the challenge of implementing digital transformation while maintaining the human elements essential to optimal outcomes.
Based on comprehensive, first-person focus group research conducted with claims and medical management executives, the latest annual report provides real-world strategies that high-performing organizations are using to deploy artificial intelligence (AI) to enhance human performance and strategic productivity while simultaneously investing in human judgment and emotional intelligence that technology cannot replicate.
'The workers' compensation industry faces a pivotal challenge: how to harness AI's potential without sacrificing empathy or outcomes,' said Rachel Fikes, Chief Experience Officer and Study Program Director at Rising Medical Solutions. 'Our research reveals that successful organizations aren't choosing between technology and human connection—they're strategically combining both to create better experiences for injured workers while improving operational efficiency and job satisfaction.'
Key Research Focus Areas
Conducted late last year, the 2024 study concentrates on three industry challenges identified by executive participants as most critical to investigate during the focus group research exercise:
Real-World Solutions for the Future
The resulting 2024 Report identifies practical use cases and actionable strategies that organizations should consider prioritizing in the next one to three years to drive competitive advantage. The report cites that organizations fully embracing AI see twice the measurable benefits compared to others, including increased productivity and profitability. However, the study emphasizes that successful digital transformation must start with understanding customer and frontline user needs rather than leading with technology.
'Claims professionals bring irreplaceable expertise and compassion that technology should work to strengthen, not eliminate,' noted Fikes. 'Our research shows that organizations achieving the best outcomes are those that use AI to handle repetitive tasks while empowering their people to build stronger relationships with injured workers.'
Continuing its tradition of industry contribution, the 2024 Study Report is available to all stakeholders at no cost. Interested parties can request the 2024 Report here.
About the Workers' Compensation Benchmarking Study
The Workers' Compensation Benchmarking Study is a national research program examining the complex forces impacting claims management in workers' compensation today. The study's mission is to advance claims management in the industry by providing both quantitative and qualitative data. Through survey research with claims leaders and practitioners nationwide, the program generates actionable intelligence for claims organizations to evaluate priorities, challenges, and strategies amongst their peers. Conceived and directed by Rising Medical Solutions, the ongoing program is a collaboration of industry executives representing diverse organizational perspectives, including the Study's Principal Researcher and Advisory Council:
About Rising Medical Solutions | We Make Lives Better.
Rising Medical Solutions is a national managed care firm that provides medical cost containment and medical care management services to the workers' compensation, auto, liability, and group health markets. Rising's mission is to 'make lives better,' by taking the pain out of the healthcare experience for those providing, receiving, and paying for medical care.
Media Contact: Rachel Fikes, [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/rising-medical-solutions-publishes-12th-annual-workers-compensation-benchmarking-study-302523092.html
SOURCE Rising Medical Solutions LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Calumet Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Explore Calumet's Fair Values from the Community and select yours Calumet (NASDAQ:CLMT) Second Quarter 2025 Results Key Financial Results Revenue: US$1.03b (down 9.4% from 2Q 2024). Net loss: US$147.9m (loss widened by 271% from 2Q 2024). US$1.70 loss per share (further deteriorated from US$0.49 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Calumet Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 8.3%. Earnings per share (EPS) missed analyst estimates significantly. Looking ahead, revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Oil and Gas industry in the US. Performance of the American Oil and Gas industry. The company's shares are down 7.4% from a week ago. Risk Analysis We should say that we've discovered 3 warning signs for Calumet (2 don't sit too well with us!) that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
22 minutes ago
- Yahoo
Emera Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Explore Emera's Fair Values from the Community and select yours Emera (TSE:EMA) Second Quarter 2025 Results Key Financial Results Revenue: CA$1.99b (up 23% from 2Q 2024). Net income: CA$154.0m (up 19% from 2Q 2024). Profit margin: 7.7% (down from 8.0% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: CA$0.52 (up from CA$0.45 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Emera Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 9.7%. Earnings per share (EPS) missed analyst estimates by 30%. Looking ahead, revenue is forecast to grow 1.4% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Electric Utilities industry in North America. Performance of the market in Canada. The company's shares are up 3.7% from a week ago. Risk Analysis Before you take the next step you should know about the 2 warning signs for Emera that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Spectral Medical Second Quarter 2025 Earnings: CA$0.007 loss per share (vs CA$0.016 loss in 2Q 2024)
Explore Spectral Medical's Fair Values from the Community and select yours Spectral Medical (TSE:EDT) Second Quarter 2025 Results Key Financial Results Revenue: CA$813.0k (up 73% from 2Q 2024). Net loss: CA$1.93m (loss narrowed by 56% from 2Q 2024). CA$0.007 loss per share (improved from CA$0.016 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Spectral Medical Earnings Insights Looking ahead, revenue is forecast to grow 72% p.a. on average during the next 3 years, compared to a 66% growth forecast for the Biotechs industry in Canada. Performance of the Canadian Biotechs industry. The company's shares are down 1.2% from a week ago. Risk Analysis Be aware that Spectral Medical is showing 4 warning signs in our investment analysis and 3 of those are significant... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
